down arrow

Zhejiang Hisoar Pharmaceutical Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000001PY2
CNY
6.14
0.07 (1.15%)

Dec 05

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Zhejiang Hisoar Pharmaceutical Co., Ltd.
Why is Zhejiang Hisoar Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 2.16%
  • The company has been able to generate a Return on Capital Employed (avg) of 2.16% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -6.39% and Operating profit at -180.98% over the last 5 years
3
Negative results in Mar 25
  • DEBT-EQUITY RATIO (HY) Highest at -1.88 %
  • INTEREST(Q) At CNY 8.04 MM has Grown at 38.17%
  • RAW MATERIAL COST(Y) Grown by 13.43% (YoY)
4
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 0.63%, its profits have risen by 49.7%
5
Underperformed the market in the last 1 year
  • The stock has generated a return of 0.63% in the last 1 year, much lower than market (China Shanghai Composite) returns of 15.18%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Zhejiang Hisoar Pharmaceutical Co., Ltd. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Zhejiang Hisoar Pharmaceutical Co., Ltd.
-100.0%
0.44
36.27%
China Shanghai Composite
15.19%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-6.39%
EBIT Growth (5y)
-180.98%
EBIT to Interest (avg)
3.95
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
0.29
Tax Ratio
1.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.16%
ROE (avg)
1.59%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.82
EV to EBIT
-44.37
EV to EBITDA
70.31
EV to Capital Employed
1.83
EV to Sales
5.18
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.12%
ROE (Latest)
-2.54%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
PRE-TAX PROFIT(Q)

At CNY 10.67 MM has Grown at 142.36%

NET PROFIT(9M)

Higher at CNY -129.51 MM

-6What is not working for the Company
DEBT-EQUITY RATIO (HY)

Highest at -1.88 %

INTEREST(Q)

At CNY 8.04 MM has Grown at 38.17%

RAW MATERIAL COST(Y)

Grown by 13.43% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.69%

Here's what is working for Zhejiang Hisoar Pharmaceutical Co., Ltd.
Pre-Tax Profit
At CNY 10.67 MM has Grown at 142.36%
over average net sales of the previous four periods of CNY -25.18 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit
At CNY 7.13 MM has Grown at 127.55%
over average net sales of the previous four periods of CNY -25.89 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (CNY MM)

Here's what is not working for Zhejiang Hisoar Pharmaceutical Co., Ltd.
Interest
At CNY 8.04 MM has Grown at 38.17%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio
Highest at -1.88 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio
Lowest at 3.69%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost
Grown by 13.43% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."